

# CELGENE CORP /DE/

## **FORM 8-K** (Current report filing)

Filed 08/22/17 for the Period Ending 08/21/17

Address	86 MORRIS AVENUE SUMMIT, NJ 07901
Telephone	(908)673-9000
CIK	0000816284
Symbol	CELG
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): August 21, 2017

**CELGENE CORPORATION**  
(Exact name of registrant as specified in its charter)

---

Delaware	001-34912	22-2711928
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

---

86 Morris Avenue, Summit, New Jersey	07901
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (908) 673-9000

---

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.**

Celgene Corporation (the “Company”) announced that, effective August 21, 2017, Michael Pehl retired from the Company as President, Hematology & Oncology. The Company thanks Michael for his years of service and wishes him well.

**ITEM 8.01 OTHER EVENTS.**

Nadim Ahmed will assume the responsibilities of President, Hematology & Oncology and will report to Scott Smith, the Company’s COO. Before this appointment, Nadim was President, Worldwide Markets, Hematology & Oncology since March 2016. Nadim served as General Manager, US Hematology & Oncology from August 2014 until March 2016. Nadim joined the Global Marketing team in 2010 as Global Head of Marketing for our Myeloma Franchise after holding positions of increasing responsibility in Clinical Development, Medical Affairs, Global and US Marketing at GSK. Nadim holds a Bachelor of Science Degree in Pharmacology from University College London, UK and a Master of Science Degree in Information Technology from Loughborough University, UK.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: August 22, 2017

By: /s/Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President  
Chief Financial Officer  
(principal financial and accounting officer)

---